

Chronic Lymphocytic Leukemia: Putting New Treatment Options Into Perspective

1. A 69-year-old man was diagnosed with CLL a year ago. He remains asymptomatic, but over the last 6 months the peripheral blood lymphocyte count has risen from $50 \times 10^9/L$ to $110 \times 10^9/L$. What management do you recommend?
 - a. chlorambucil plus prednisone
 - b. bendamustine
 - c. fludarabine, cyclophosphamide, and rituximab
 - d. continued monitoring
2. Which cytogenetic abnormality detected in CLL cells by FISH testing is associated with the shortest time to disease progression and resistance to therapy?
 - a. del(13q)
 - b. del(17p)
 - c. del(11q)
 - d. trisomy 12
3. A 55-year-old woman with symptomatic CLL [no del(17p)] is referred to you for treatment. She has diabetes and hypertension and her creatinine clearance is 40 mL/min. Which of the following options is **not** preferred for initial therapy?
 - a. fludarabine, cyclophosphamide, and rituximab
 - b. chlorambucil plus prednisone
 - c. bendamustine
 - d. alemtuzumab
4. A 76-year-old man with symptomatic CLL [no del(17p)] is referred to you for treatment. He is in excellent health and has normal renal function. According to guidelines, which is the preferred initial therapy?
 - a. bendamustine
 - b. fludarabine, cyclophosphamide, and rituximab
 - c. chlorambucil plus prednisone
 - d. alemtuzumab
5. You have recommended alemtuzumab as second-line therapy for CLL in an otherwise healthy 71-year-old man. What else do you recommend?
 - a. weekly CMV PCR
 - b. cotrimoxazole
 - c. acyclovir
 - d. all of the above

Answer Sheet - Retain a copy for your records!

1. A B C D
2. A B C D
3. A B C D
4. A B C D
5. A B C D

**Please rate this CME exercise using the scale:
A = inadequate, B = minimally adequate,
C = satisfactory, D = very good, E = excellent.**

Did the article in this issue meet the stated objectives?

1. A B C D E

Was the information relevant to your practice in oncology?

2. A B C D E

Were your educational needs met regarding these topics?

3. A B C D E

Was the CME posttest scientifically rigorous?

4. A B C D E

Please PRINT clearly:

Name: _____

Address: _____

City: _____

State: _____ ZIP: _____

E-mail address: _____

Submit to:

James Karger
UT Southwestern Medical Center
Fax: 214-648-2317
E-mail: James.Karger@UTSouthwestern.edu

Course #: EM1005